| DOI | Resolve DOI: https://doi.org/10.1158/1538-7445.AM2016-1216 |
|---|
| Author | Search for: Jaramillo, Maria L.1; Search for: Meury, Luc1; Search for: Jolicoeur, Normand1; Search for: Banville, Myruam1; Search for: Tao, Limei1; Search for: McCourt, Maureen O'Connor1 |
|---|
| Affiliation | - National Research Council of Canada. Human Health Therapeutics
|
|---|
| Format | Text, Article |
|---|
| Conference | AACR 107th Annual Meeting 2016, April 16-20, 2016, New Orleans, LA |
|---|
| Abstract | One of the most promising and fastest growing classes of cancer therapeutics builds on the molecular targeting abilities of antibodies by combining them with drugs to generate highly specific antibody-drug conjugates (ADCs). However, the development of ADCs requires time-consuming selection of the antibody for every target and cancer type. Screening technologies based on the use of conjugated secondary antibodies provide a fast and efficient surrogate assay from which to identify which antibodies are best internalized and suitable for immunoconjugate development into ADCs. |
|---|
| Publication date | 2016-07-15 |
|---|
| In | |
|---|
| Series | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| NPARC number | 23000714 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 567ed20b-bd54-4fdf-a87b-b69bdd6ef870 |
|---|
| Record created | 2016-08-31 |
|---|
| Record modified | 2020-03-16 |
|---|
